Type I Diabetes Impact Award (DP3)

The summary for the Type I Diabetes Impact Award (DP3) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Type I Diabetes Impact Award (DP3)
	CFDA Number:	93.847
	CFDA Description:	Diabetes, Digestive, and Kidney Diseases Extramural Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Food and Nutrition Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-DK-10-012
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Sep 16, 2010
	Creation Date:	Sep 16, 2010
	Original Closing Date for Applications:	Mar 11, 2011
	Current Closing Date for Applications:	Mar 11, 2011
	Archive Date:	Apr 11, 2011
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$30,000,000
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: This FOA issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, encourages Research Project Grant (DP3) applications from institutions/organizations proposing groundbreaking original research addressing fundamental questions or major obstacles in Type 1 Diabetes Research, including studies that challenge current dogma. Projects must clearly address a compelling unanswered question in Type 1 Diabetes research.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-dk-10-012.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Pediatric Centers of Excellence in Nephrology (P50); • Nutrition Obesity Research Centers (P30); • George M. OBrien Kidney Research Core Centers (P30); • Cooperative Study Group for Autoimmune Disease Prevention (U01); • Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24); • PROTEOMIC AND METABOLOMIC APPROACHES TO DIAGNOSE DIABETES AND PRE-DIABETES; • MOLECULAR THERAPY CORE CENTERS; • PILOT AND FEASIBILITY PROGRAM IN HUMAN ISLET BIOLOGY; • DIABETES ENDOCRINOLOGY RESEARCH CENTERS; • CYSTIC FIBROSIS RESEARCH AND TRANSLATION CORE CENTERS